Literature DB >> 9353393

Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.

C T Dooley1, C G Spaeth, I P Berzetei-Gurske, K Craymer, I D Adapa, S R Brandt, R A Houghten, L Toll.   

Abstract

Fifteen hexapeptides having high affinity for the opioid-like receptor ORL1 were identified from a combinatorial library containing more than 52 million different hexapeptides. The five compounds with the highest affinity were characterized further by use of a variety of in vitro models. Binding studies indicated that these five peptides have affinity for ORL1 in the nanomolar range, similar to the recently discovered endogenous ligand called nociceptin and orphanin FQ (N/OFQ). The activity of these compounds was investigated in three different assays: stimulation of [35S]GTPgammaS binding and inhibition of forskolin-stimulated cAMP accumulation in Chinese hamster ovary cells transfected with ORL1, and inhibition of electrically induced contractions in the mouse vas deferens. In each assay, the five hexapeptides acted as partial agonists. The EC50 values for stimulation of [35S]GTPgammaS binding and inhibition of cAMP accumulation were in the range of that for N/OFQ, but maximal effects ranged from 70 to 90% of N/OFQ in the cAMP assay, and 30 to 60% of N/OFQ in the GTPgammaS assay. The positive hexapeptides identified were found to have minimal structural similarity to N/OFQ. The peptides are positively charged, which could enable them to bind to the negatively charged second extracellular loop thought to be a likely binding site for N/OFQ.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353393

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  44 in total

1.  Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors.

Authors:  K Flau; A Redmer; S Liedtke; M Kathmann; E Schlicker
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.

Authors:  Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

Review 3.  In vitro and direct in vivo testing of mixture-based combinatorial libraries for the identification of highly active and specific opiate ligands.

Authors:  Richard A Houghten; Colette T Dooley; Jon R Appel
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

4.  New peptide inhibitors of type IB topoisomerases: similarities and differences vis-a-vis inhibitors of tyrosine recombinases.

Authors:  David F Fujimoto; Clemencia Pinilla; Anca M Segall
Journal:  J Mol Biol       Date:  2006-08-24       Impact factor: 5.469

5.  Rare diseases and orphan drugs.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

6.  Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.

Authors:  Anna Rizzi; Daniela Rizzi; Giuliano Marzola; Domenico Regoli; Bjarne Due Larsen; Jorgen Soberg Petersen; Girolamo Calo'
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

7.  Functional pharmacological characterization of SER100 in cardiovascular health and disease.

Authors:  Inmaculada C Villar; Kristen J Bubb; Amie J Moyes; Eva Steiness; Trygve Gulbrandsen; Finn Olav Levy; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

8.  The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.

Authors:  Ling Jong; Nurulain Zaveri; Lawrence Toll
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

9.  Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.

Authors:  Lawrence Toll; Taline V Khroyan; Willma E Polgar; Faming Jiang; Cris Olsen; Nurulain T Zaveri
Journal:  J Pharmacol Exp Ther       Date:  2009-09-22       Impact factor: 4.030

Review 10.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.